Next Phase Newsletter

A venture capital firm based in the US is seeking to invest in Pre-Seed to Series A companies, with typical check sizes between $100K and $1M. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from outside of North America. 
 
Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies. 
 
The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A group founded by medical device experts seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel,  pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and as a result, is currently focused on companies willing to start a joint venture in China. 
 
The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses. 
 
The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A multi-asset strategy single family office is involved in real estate management and venture investments. The group has offices in US and China, and the firm’s venture investment arm seeks to invest in early-stage, innovative technology companies. The firm typically engages in seed to series A rounds and prefers life science and healthcare companies with high-tech components. The initial check size from $100K-1M USD. The firm is interested in companies based in the US. 

The firm possesses extensive expertise in cross border investments and collaboration. The firm can leverage its local networks and resources if their portfolio companies have the willingness to expand their businesses in China on various fronts, such as securing additional funding. Because of this unique strategic advantage, the firm maintains a special interest in companies with a China angle and firms with products or technologies suited for the Chinese market. 

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment. 
 
The firm seeks life science and healthcare companies that incorporate high-tech components, such as AI in healthcare and life sciences. The firm is open to considering medical devices, and digital health, and its opportunistic regarding subsectors and indications. Due to the scientific background of its team, the firm is particularly interested in chronic diseases such as diabetes and cardiovascular diseases. 
 
There are no specific requirements for the company and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A USA-based venture capital firm focuses on biotech investments with particular interest in the following indications: oncology, immunology, CNS/neurology, among others. The firm also invests in rare and orphan diseases. The firm is generally stage agnostic, and can invest in anywhere from pre-clinical to pre-launch, commercial stage companies. The firm is capable of investing up to $15M over the life of the company, and is open to acting as either the lead/co-lead or co-investor. 
 
The firm focuses on investments in therapeutics companies across all stages of development, from pre-clinical, clinical, to commercial stage. The firm is most interested in indications of high unmet medical need, including oncology, immunology, neurology, and rare diseases and may seek assets in other indications on a case-by-case basis. 
 
The firm seeks to work with companies backed by a experienced management team with strong scientific expertise. The firm invests in both public and private companies, and is open to acting as either the lead/co-lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A biotech early stage investment firm invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round. 
 
The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms. 
 
The firm does not have any specific requirements for companies and their management teams. Th firm can act as a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the USA is currently investing from their second fund. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe. 
 
The firm invests in medical device, diagnostics, and digital health companies. The firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology. 
 
The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.